Literature DB >> 20220821

Accelerating HIV vaccine development.

Wayne C Koff1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20220821     DOI： 10.1038/464161a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  13 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

Review 2.  HIV vaccine design: insights from live attenuated SIV vaccines.

Authors:  Wayne C Koff; Philip R Johnson; David I Watkins; Dennis R Burton; Jeffrey D Lifson; Kim J Hasenkrug; Adrian B McDermott; Alan Schultz; Timothy J Zamb; Rosanne Boyle; Ronald C Desrosiers
Journal:  Nat Immunol       Date:  2006-01       Impact factor: 25.606

3.  HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Authors:  Toshiyuki Miura; Chanson J Brumme; Mark A Brockman; Zabrina L Brumme; Florencia Pereyra; Brian L Block; Alicja Trocha; Mina John; Simon Mallal; P Richard Harrigan; Bruce D Walker
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

Review 4.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

5.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

6.  Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Authors:  Scott G Hansen; Cassandra Vieville; Nathan Whizin; Lia Coyne-Johnson; Don C Siess; Derek D Drummond; Alfred W Legasse; Michael K Axthelm; Kelli Oswald; Charles M Trubey; Michael Piatak; Jeffrey D Lifson; Jay A Nelson; Michael A Jarvis; Louis J Picker
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

7.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

Review 9.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

10.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Authors:  Ann J Hessell; Pascal Poignard; Meredith Hunter; Lars Hangartner; David M Tehrani; Wim K Bleeker; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440
View more
  15 in total

1.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 2.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 3.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 4.  Redesigning the AIDS response for long-term impact.

Authors:  Heidi J Larson; Stefano Bertozzi; Peter Piot
Journal:  Bull World Health Organ       Date:  2011-10-06       Impact factor: 9.408

Review 5.  Novel directions in HIV-1 vaccines revealed from clinical trials.

Authors:  Jean-Louis Excler; Georgia D Tomaras; Nina D Russell
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

6.  Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Authors:  Andrew Rosa Borges; Lindsay Wieczorek; Benitra Johnson; Alan J Benesi; Bruce K Brown; Richard D Kensinger; Fred C Krebs; Brian Wigdahl; Robert Blumenthal; Anu Puri; Francine E McCutchan; Deborah L Birx; Victoria R Polonis; Cara-Lynne Schengrund
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

7.  GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.

Authors:  Emma L Mohr; Jinhua Xiang; James H McLinden; Thomas M Kaufman; Qing Chang; David C Montefiori; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

8.  Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy.

Authors:  Benjamin Mason Meier; Kristen Nichole Brugh; Yasmin Halima
Journal:  Public Health Ethics       Date:  2012-12-05       Impact factor: 1.940

9.  A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Michael Piatak; Henry T Robertson; David B Allison; Andrew J Bett; Danilo R Casimiro; John W Shiver; Nancy A Wilson; Jeffrey D Lifson; Wayne C Koff; David I Watkins
Journal:  Vaccine       Date:  2012-05-06       Impact factor: 3.641

Review 10.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.